Related Experiment Video
Updated: May 27, 2026
07:42
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
Published on: November 26, 2015
CD133 Immunoexpression in Prostatic Acinar Adenocarcinomas.
Adrian Mihai Stoiculescu1, Oana-Iulia Crețu2, Bianca Cătălina Andreiana2
1PhD Student, Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania.
Current Health Sciences Journal
|May 26, 2026
Summary
CD133 immunoexpression is elevated in aggressive prostatic acinar adenocarcinomas (PAA). This marker may help identify patients with PAA who have a poorer prognosis and require specific therapies.
Area of Science:
- Oncology
- Urology
- Cancer Biology
Background:
- Prostatic acinar adenocarcinomas (PAA) present significant challenges in diagnosis and treatment.
- Tumor cell stemness contributes to tumor survival and the development of aggressive phenotypes.
Purpose of the Study:
- To investigate the role of CD133 immunoexpression in prostatic acinar adenocarcinomas.
- To correlate CD133 expression with clinico-epidemiological and histopathological features of PAA.
Main Methods:
- Analysis of CD133 immunoexpression in 55 PAA cases.
- Correlation of CD133 reactions with patient age, serum PSA, tumor subtypes, grading, and invasion.
Main Results:
- CD133 expression was observed in tumor and stromal cells.
- Significantly higher CD133 reactions were found in PAA from elderly patients and those with elevated PSA.
- Increased CD133 expression correlated with aggressive PAA subtypes, advanced grading, and perineural/lymphovascular invasion.
Conclusions:
- CD133 may identify stem cell reservoirs within PAA.
- CD133 immunoexpression is associated with aggressive PAA behavior.
- CD133 could aid in stratifying patients for targeted therapy.
